CTIS2023-509678-52-00招募中1 期
A Phase IB/IIA, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 following Intravenous Infusion in Patients with Prodromal or Mild To Moderate Alzheimer’s Disease - BP42155
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 256
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Age 50 to 85 years (inclusive) at screening, 2. Probable mild to moderate AD dementia (consistent with NIA-AA core clinical criteria for probable AD dementia) (McKhann et al 2011) or prodromal AD (consistent with the NIA-AA diagnostic criteria and guidelines for mild cognitive impairment due to AD) (Albert et al 2011), 3. Mini-Mental State Examination (MMSE) score of 18 to 28 points, inclusive, within 84 days before baseline, 4. Clinical Dementia Rating-Global Score (CDR-GS) of 0.5, 1, or 2 within 84 days before baseline, 5. Positive amyloid PET scan (cut-off: > 50 Centiloid units) within 12 months before baseline, 6. In case of treatment with symptomatic AD medications, dosing regimen must be stable for at least 8 weeks prior to baseline and until randomization
排除标准
- •1. Any condition other than AD that may affect cognition, 2. Significant cerebral abnormalities, 3. History or presence of intracranial mass (e.g., glioma, meningioma) that could potentially impair cognition, 4. History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder, Cancer, unless cured or currently not needing treatment. Note: History of major depression is acceptable, if participant has had no episode within the past year, or is considered in remission, or depression is controlled by treatment, 5. History of any clinically significant hematological diseases, clinically significant ophthalmologic disease or chronic kidney disease, 6. Atrial fibrillation, cardiovascular disease or uncontrolled hypertension
研究者
相似试验
已完成
1 期
Study of the Drug BTD-001 in Young Adults and Adolescents with Down SyndromeDown syndromeHuman Genetics and Inherited Disorders - Down's syndromeACTRN12612000652875ovotech (Australia) Pty Limited90
招募中
1 期
A multiple-ascending dose study of RO7126209 in patients with prodromal or mild to moderate Alzheimer's diseaseAlzheimer's diseaseJPRN-jRCT2051230101uka Kulic MD210
进行中（未招募）
1 期
A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohn’s DiseaseMedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856Crohn's diseaseEUCTR2018-002001-65-GBniversity of Birmingham36
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitisModerate to severe ulcerative colitisEUCTR2019-004090-50-ESONCOSTELLAE S.L.32
进行中（未招募）
1 期
A study to evaluate safety and processing by body of GDC-6988 in healthy adults receiving albuterol as a pretreatment medicatioSafety and pharmacokinetics of multiple ascending doses of GDC-6988 with and without albuterol pretreatment in healthy adult subjectsISRCTN15406513F. Hoffmann-La Roche Ltd30